Brandon Couillard

Q: What is Brandon Couillard's success rate?

Brandon Couillard currently has a success rate of 99.64403343149937.

Q: What is the average return of Brandon Couillard's calls?

Their stock ratings have generated an average return of 11.041479649215258.

Wells Fargo | Healthcare

Brandon Couillard is an analyst from Wells Fargo specializing in the Healthcare sector. Ranked #906 out of 4537 analysts, they have issued 53 stock ratings with a success rate of 99.64% and an average return of 11.04%.

Brandon Couillard has a well-established track record, with 53 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 99.64% and an average return of 11.04%, underscoring their expertise and ability to identify winning opportunities for investors.

#906

Out of 4537

Total Ratings

+99.64%

Success Rate

+11.04%

Average Return

Recent Ratings Analysis

WGS

Buy

Feb 09, 2026

Target

$155.00

Current

$94.78

Performance

3.88%

Brandon Couillard rated WGS as Overweight on Feb 09, 2026, setting a price target of 155. Shares have remained stable near 94.78, leaving the 155 target still in play.

TECH

Buy

Feb 06, 2026

Target

$76.00

Current

$64.80

Performance

-2.96%

On Feb 06, 2026, TECH was given a Overweight rating by Brandon Couillard, with a target price of 76. The stock traded sideways with a -2.96% move, keeping the bullish thesis unresolved.

MLAB

Hold

Feb 04, 2026

Target

$94.00

Current

$91.95

Performance

0.46%

MLAB received a Equal-Weight rating from Brandon Couillard on Feb 04, 2026, aiming for 94. Shares remained flat at 91.95, aligning with the neutral rating.

RVTY

Hold

Feb 03, 2026

Target

$110.00

Current

$104.75

Performance

3.58%

On Feb 03, 2026, Brandon Couillard published a Equal-Weight outlook on RVTY, with a target of 110. Sideways action left the Hold view intact, with no major move since 104.75.

GH

Buy

Dec 15, 2025

Target

$120.00

Current

$105.03

Performance

2.30%

Brandon Couillard on Dec 15, 2025 assigned GH a Overweight rating, with a price target of 120. The recommendation remains pending validation as shares consolidate around 105.03.

CDNA

Hold

Dec 15, 2025

Target

$18.00

Current

$20.57

Performance

3.31%

On Dec 15, 2025, Brandon Couillard reaffirmed CDNA with a Equal-Weight rating, targeting 18. The neutral call matched muted market action of 3.31%.

DHR

Hold

Dec 15, 2025

Target

$240.00

Current

$219.75

Performance

-3.84%

DHR was rated Equal-Weight by Brandon Couillard on Dec 15, 2025, with a price objective of 240. Flat performance suggests the Hold view was reasonable.

MRVI

Buy

Dec 15, 2025

Target

$4.50

Current

$3.12

Performance

-14.99%

On Dec 15, 2025, Brandon Couillard initiated coverage on MRVI with a Overweight rating and target of 4.5. The Buy call has yet to be validated as shares remain 1.38 away from the target.

MTD

Hold

Dec 15, 2025

Target

$1450.00

Current

$1400.33

Performance

-0.86%

Brandon Couillard issued a Equal-Weight recommendation for MTD on Dec 15, 2025, price target set at 1450. The rating was appropriate for a consolidating market trading near 1400.33.

NTRA

Hold

Dec 15, 2025

Target

$205.00

Current

$211.65

Performance

-7.33%

On Dec 15, 2025, NTRA was evaluated by Brandon Couillard, who gave a Equal-Weight rating and target of 205. The Hold call avoided chasing into subsequent weakness of 7.33%.

RGEN

Buy

Dec 15, 2025

Target

$190.00

Current

$143.06

Performance

-10.91%

Brandon Couillard rated RGEN as Overweight on Dec 15, 2025, setting a price target of 190. The stock has underperformed, dropping 10.91% despite the bullish target of 190.

TMO

Buy

Dec 15, 2025

Target

$675.00

Current

$539.80

Performance

-6.27%

On Dec 15, 2025, TMO was given a Overweight rating by Brandon Couillard, with a target price of 675. Despite the Buy call, shares fell from 539.8 to 539.8, challenging the optimistic stance.

WAT

Hold

Dec 15, 2025

Target

$415.00

Current

$327.02

Performance

-15.15%

WAT received a Equal-Weight rating from Brandon Couillard on Dec 15, 2025, aiming for 415. The Hold stance proved prudent, with the market softening by 15.15%.

BRKR

Buy

Dec 15, 2025

Target

$55.00

Current

$41.58

Performance

-8.96%

On Dec 15, 2025, Brandon Couillard published a Overweight outlook on BRKR, with a target of 55. Market action contradicted the Buy thesis, as shares slipped to 41.58.

BLLN

Hold

Dec 01, 2025

Target

$110.00

Current

$91.94

Performance

-18.67%

Brandon Couillard on Dec 01, 2025 assigned BLLN a Equal-Weight rating, with a price target of 110. The call successfully avoided chasing as shares lost 18.67%.

A

Buy

Nov 25, 2025

Target

$175.00

Current

$129.00

Performance

-17.94%

On Nov 25, 2025, Brandon Couillard reaffirmed A with a Overweight rating, targeting 175. Shares slid 17.94% despite the recommendation, highlighting downside risks.

EXAS

Hold

Nov 24, 2025

Target

$105.00

Current

$103.35

Performance

2.32%

EXAS was rated Hold by Brandon Couillard on Nov 24, 2025, with a price objective of 105. Flat performance suggests the Hold view was reasonable.

MYGN

Hold

Nov 05, 2025

Target

$6.50

Current

$5.08

Performance

-22.80%

On Nov 05, 2025, Brandon Couillard initiated coverage on MYGN with a Equal-Weight rating and target of 6.5. The rating matched the stock’s inability to hold above 5.08.

BIO

Hold

Oct 30, 2025

Target

$340.00

Current

$299.96

Performance

-1.53%

Brandon Couillard issued a Equal-Weight recommendation for BIO on Oct 30, 2025, price target set at 340. The rating was appropriate for a consolidating market trading near 299.96.

AVTR

Buy

Aug 04, 2025

Target

$16.00

Current

$11.16

Performance

-1.24%

On Aug 04, 2025, AVTR was evaluated by Brandon Couillard, who gave a Overweight rating and target of 16. So far, the Buy call awaits clearer momentum, with shares flat at 11.16.

HSIC

Hold

Jan 23, 2025

Target

$80.00

Current

$81.02

Performance

8.39%

Brandon Couillard rated HSIC as Hold on Jan 23, 2025, setting a price target of 80. Despite the Hold call, shares climbed 8.39% to 81.02, revealing unexpected momentum.

ALGN

Buy

Jan 23, 2025

Target

$260.00

Current

$196.27

Performance

-16.44%

On Jan 23, 2025, ALGN was given a Buy rating by Brandon Couillard, with a target price of 260. Despite the Buy call, shares fell from 196.27 to 196.27, challenging the optimistic stance.

Frequency Asked Questions

Who is Brandon Couillard?

Brandon Couillard is an analyst from Wells Fargo specializing in the Healthcare sector.

What is Brandon Couillard's success rate?

Brandon Couillard currently has a success rate of +99.64%.

How many ratings has Brandon Couillard issued?

Brandon Couillard has issued 53 stock ratings so far.

What is the average return of Brandon Couillard's calls?

Their stock ratings have generated an average return of +11.04%.

What is Brandon Couillard's ranking?

Brandon Couillard is ranked #906 out of 4537 analysts.

What types of ratings does Brandon Couillard give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Brandon Couillard?

You can follow Brandon Couillard by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Brandon Couillard?

Their latest rating was a Buy on WGS issued on 2026-02-09.